Otitopic, which recently announced that it received a new patent for the us of inhaled aspirin for the treatment of myocardial infarction, now says that it also plans to develop its Asprihale aspirin DPI for the treatment of lung cancer.
The company cites published studies showing lower risk of lung cancer with aspirin use and the potential of aspirin to inhibit tumor growth and metastasis. According to Otitopic, tox studies of its formulation suggest that Asprihale has the potential to be a safer therapy than oral aspirin.
Otitopic Founder and CEO Kambiz Yadidi tells OINDPnews that the company plans to conduct a pre-clinical proof of concept study and will meet soon with the FDA to discuss further clinical development.
Read the Otitopic press release.
